Physician profile
Seth G Kates
NPI 1760473557
$64,458.31
in general payments reported to CMS, 2019-2025
43 companies · $4,227 in 2025
The $4,227 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,756 · 2020: $5,070 · 2021: $8,435 · 2022: $19K · 2023: $15K · 2024: $4,155 · 2025: $4,227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Travel and Lodging: $84.78 · Education: $47.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,161.90 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,050.00 |
| Travel and Lodging | $84.78 |
| Education | $47.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $27,593.70 | 2019-2022 | |
| Abbvie INC. | $16,475.10 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $2,621.68 | 2019-2025 | |
| Amgen INC. | $1,826.17 | 2019-2025 | Otezla, Otezla, Enbrel |
| Janssen Biotech, INC. | $1,359.49 | 2019-2025 | Tremfya, Stelara, Simponi |
| Sun Pharmaceutical Industries INC. | $1,358.75 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Lilly USA, LLC | $1,353.36 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $1,122.64 | 2019-2025 | |
| Incyte Corporation | $1,006.25 | 2021-2025 | Opzelura |
| Genzyme Corporation | $984.94 | 2019-2025 | |
| Galderma Laboratories, L.P. | $964.91 | 2019-2025 | Nemluvio, Aklief |
| Leo Pharma INC. | $926.53 | 2019-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $879.03 | 2019-2025 | Dupixent, Libtayo |
| Ucb, INC. | $807.59 | 2019-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $675.78 | 2022-2025 | Sotyktu |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Kates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.